Biotech

All Articles

Pfizer takes $230M struck after axing stopped working DMD gene treatment

.Pfizer's stage 3 Duchenne muscle dystrophy (DMD) gene therapy failing has actually blown a $230 mil...

AC Immune observes 'spots' prospective in Alzheimer's medicine data

.After much more than twenty years of work with neurodegenerative illness, Swiss biotech air conditi...

GSK loses ph. 2 HPV vaccine over absence of best-in-class potential

.GSK has actually broken up a period 2 individual papillomavirus (HPV) vaccination from its own pipe...

OS Treatments refiles $6M IPO to money HER2 medicine, preclinical ADCs

.Operating system Therapies will provide on the NYSE American stock substitution this morning using ...

ALX's fizzling CD47 action cost sends sell spiraling down

.ALX Oncology's stage 2 gastric cancer cells action fee has deteriorated. After finding its CD47 blo...

Ionis axes eye condition coming from targets of Roche-partnered prospect after data dissatisfy

.Another of Ionis Pharmaceuticals' crucial midphase readouts has fallen short of assumptions, causin...

Biogen's chief executive officer pointed out no high-risk handle 2023. He prepares to be vibrant

.While Biogen's pharma peers are hunting for late-stage assets along with little bit of threat, chie...

Instil refills pipeline in $2B biobucks handle ImmunOnco

.Instil Biography has actually been a biotech seeking a pipeline after it junked its lead assets ove...

Biogen leaves Denali Alzheimer's collab

.Biogen has actually handed back civil rights to an early Alzheimer's health condition course to Den...

Takeda taps new head people oncology company-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of notable management hirings, shootings and...